Mitochondrial and nuclear genes of mitochondrial components in cancer

Current Genomics

Volumn 10, Issue 4, 2009, Pages 281-293

  Kirches, Elmar ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA DIRECTED DNA POLYMERASE GAMMA; FRATAXIN; FUMARATE HYDRATASE; HEXOKINASE; HEXOKINASE ISOENZYME; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; NUCLEAR PROTEIN; REACTIVE OXYGEN METABOLITE; SELENOPROTEIN; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

CANCER CELL; CANCER DIAGNOSIS; CANCER GENETICS; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CARCINOGENICITY; CHROMOSOME LOSS; CITRIC ACID CYCLE; DNA MICROARRAY; DNA POLYMORPHISM; EARLY DIAGNOSIS; ENERGY METABOLISM; GENE INACTIVATION; GENETIC DRIFT; HUMAN; HYPOXIA; KIDNEY CARCINOMA; MISSENSE MUTATION; MITOCHONDRIAL GENE; MITOCHONDRIAL GENOME; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROSTATE CANCER; RESPIRATORY CHAIN; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 68749097257     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920209788488517     Document Type: Review

References (101)

1. Warburg, O. On respiratory impairment in cancer cells. Science 1956, 124, 269-270.
2. Warburg, O. On the origin of cancer cells. Science, 1956, 123, 309-314.
3. Wachsberger, P. R.; Gressen, E. L.; Bhala, A.; Bobyock, S. B.; Storck, C.; Coss, R. A.; Berd, D.; Leeper, D. B. Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. Melanoma Res., 2002, 12, 35-43.
4. Chang, S.; Lee, S.; Lee, C.; Kim, J. I.; Kim, Y. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology, 2000, 55, 448-452.
5. Thupari, J. N.; Pinn, M. L.; Kuhajda, F. P. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun., 2001, 285, 217-223.
6. Weinhouse, S. On respiratory impairment in cancer cells. Science 1956, 124, 267-269.
7. Zu, X. L.; Guppy, M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun., 2004, 313, 459-465.
8. Bustamante, E.; Pedersen, P. L. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc. Natl. Acad. Sci. USA, 1977, 74, 3735-3739.
9. Mathupala, S. P.; Ko, Y. H.; Pedersen, P. L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene, 2006, 25, 4777-4786.
10. Rempel, A.; Bannasch, P.; Mayer, D. Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim. Biophys. Acta, 1994, 1219, 660-668.
11. Mayer, D.; Klimek, F.; Rempel, A.; Bannasch, P. Hexokinase expression in liver preneoplasia and neoplasia. Biochem. Soc. Trans., 1997, 25, 122-127.
12. Pedersen, P. L.; Mathupala, S.; Rempel, A.; Geschwind, J. F.; Ko, Y. H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta, 2002, 1555, 14-20.
13. Wilson, J. E. Hexokinases. Rev. Physiol. Biochem. Pharmacol., 1995, 126, 65-198.
14. Wilson, J. E. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol., 2003, 206, 2049-2057.
15. Goel, A.; Mathupala, S. P.; Pedersen, P. L. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J. Biol. Chem., 2003, 278, 15333-15340.
16. Rempel, A.; Mathupala, S. P.; Griffin, C. A.; Hawkins, A. L.; Pedersen, P. L. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res., 1996, 56, 2468-2471.
17. Johansson, T.; Berrez, J. M.; Nelson, B. D. Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma. Biochem. Biophys. Res. Commun., 1985, 133, 608-613.
18. Rempel, A.; Bannasch, P.; Mayer, D. Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. Biochem. J., 1994, 303, 269-274.
19. Mathupala, S. P.; Rempel, A.; Pedersen, P. L. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J. Biol. Chem., 1995, 270, 16918-16925.
20. Nakashima, R. A.; Mangan, P. S.; Colombini, M.; Pedersen, P. L. Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N′-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry, 1986, 25, 1015-1021.
21. Arora, K. K.; Pedersen, P. L. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J. Biol. Chem., 1988, 263, 17422-17428.
22. Pastorino, J. G.; Hoek, J. B. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr. Med. Chem., 2003, 10, 1535-1551.
23. Vyssokikh, M. Y.; Brdiczka, D. The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. Acta Biochim. Pol., 2003, 50, 389-404.
24. Zaid, H.; Abu-Hamad, S.; Israelson, A.; Nathan, I.; Shoshan-Barmatz, V. The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ., 2005, 12, 751-760.
25. Godinot, C.; de Laplanche, E.; Hervouet, E.; Simonnet, H. Actuality of Warburg's views in our understanding of renal cancer metabolism. J. Bioenerg. Biomembr., 2007, 39, 235-241.
26. Neumann, H. P.; Wiestler, O. D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet, 1991, 337, 1052-1054.
27. Brauch, H.; Kishida, T.; Glavac, D.; Chen, F.; Pausch, F.; Hofler, H.; Latif, F.; Lerman, M. I.; Zbar, B.; Neumann, H. P. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum. Genet., 1995, 95, 551-556.
28. Baysal, B. E.; Ferrell, R. E.; Willett-Brozick, J. E.; Lawrence, E. C.; Myssiorek, D.; Bosch, A.; van der Mey, A.; Taschner, P. E.; Rubinstein, W. S.; Myers, E. N.; Richard, C. W., 3rd; Cornelisse, C. J.; Devilee, P.; Devlin, B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000, 287, 848-851.
29. Gonzalez, C.; Almaraz, L.; Obeso, A.; Rigual, R. Carotid body chemoreceptors: from natural stimuli to sensory discharges. Physiol. Rev., 1994, 74, 829-898.
30. Semenza, G. L. Perspectives on oxygen sensing. Cell 1999, 98, 281-284.
31. Bunn, H. F.; Poyton, R. O. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev., 1996, 76, 839-885.
32. Arias-Stella, J.; Bustos, F. Chronic hypoxia and chemodectomas in bovines at high altitudes. Arch Pathol. Lab. Med., 1976, 100, 636-639.
33. Arias-Stella, J.; Valcarcel, J. Chief cell hyperplasia in the human carotid body at high altitudes; physiologic and pathologic significance. Hum. Pathol., 1976, 7, 361-373.
34. Edwards, C.; Heath, D.; Harris, P.; Castillo, Y.; Kruger, H.; Arias-Stella, J. The carotid body in animals at high altitude. J. Pathol., 1971, 104, 231-238.
35. Saldana, M. J.; Salem, L. E.; Travezan, R. High altitude hypoxia and chemodectomas. Hum. Pathol., 1973, 4 (2), 251-263.
36. Nurse, C. A.; Vollmer, C. Role of basic FGF and oxygen in control of proliferation, survival, and neuronal differentiation in carotid body chromaffin cells. Dev. Biol., 1997, 184, 197-206.
37. Lack, E. E.; Cubilla, A. L.; Woodruff, J. M. Paragangliomas of the head and neck region. A pathologic study of tumors from 71 patients. Hum. Pathol., 1979, 10, 191-218.
38. Lack, E. E.; Perez-Atayde, A. R.; Young, J. B. Carotid body hyperplasia in cystic fibrosis and cyanotic heart disease. A combined morphometric, ultrastructural, and biochemical study. Am. J. Pathol., 1985, 119, 301-314.
39. Stiller, D.; Katenkamp, D.; Kuttner, K. Jugular body tumors: hyperplasias or true neoplasms? Light and electron microscopical investigations. Virchows Arch. A Pathol. Anat. Histol., 1975, 365, 163-177.
40. Briere, J. J.; Favier, J.; Benit, P.; El Ghouzzi, V.; Lorenzato, A.; Rabier, D.; Di Renzo, M. F.; Gimenez-Roqueplo, A. P.; Rustin, P. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet., 2005, 14 (21), 3263-3269.
41. Ishii, T.; Yasuda, K.; Akatsuka, A.; Hino, O.; Hartman, P. S.; Ishii, N. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res., 2005, 65, 203-209.
42. Slane, B. G.; Aykin-Burns, N.; Smith, B. J.; Kalen, A. L.; Goswami, P. C.; Domann, F. E.; Spitz, D. R. Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res., 2006, 66, 7615-7620.
43. Niemann, S.; Muller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 2000, 26, 268-270.
44. Baysal, B. E.; Willett-Brozick, J. E.; Lawrence, E. C.; Drovdlic, C. M.; Savul, S. A.; McLeod, D. R.; Yee, H. A.; Brackmann, D. E.; Slattery, W. H., 3rd; Myers, E. N.; Ferrell, R. E.; Rubinstein, W. S. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J. Med. Genet., 2002, 39, 178-183.
45. Astuti, D.; Latif, F.; Dallol, A.; Dahia, P. L.; Douglas, F.; George, E.; Skoldberg, F.; Husebye, E. S.; Eng, C.; Maher, E. R. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 2001, 69, 49-54.
46. Vanharanta, S.; Buchta, M.; McWhinney, S. R.; Virta, S. K.; Peczkowska, M.; Morrison, C. D.; Lehtonen, R.; Januszewicz, A.; Jarvinen, H.; Juhola, M.; Mecklin, J. P.; Pukkala, E.; Herva, R.; Kiuru, M.; Nupponen, N. N.; Aaltonen, L. A.; Neumann, H. P.; Eng, C. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet., 2004, 74, 153-159.
47. Ricketts, C.; Woodward, E. R.; Killick, P.; Morris, M. R.; Astuti, D.; Latif, F.; Maher, E. R. Germline SDHB mutations and familial renal cell carcinoma. J. Natl. Cancer Inst., 2008, 100, 1260-2.
48. Ni, Y.; Zbuk, K. M.; Sadler, T.; Patocs, A.; Lobo, G.; Edelman, E.; Platzer, P.; Orloff, M. S.; Waite, K. A.; Eng, C. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am. J. Hum. Genet., 2008, 83, 261-268.
49. Gellera, C.; Uziel, G.; Rimoldi, M.; Zeviani, M.; Laverda, A.; Carrara, F.; DiDonato, S. Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology, 1990, 40, 495-499.
50. Liochev, S. I.; Fridovich, I., Fumarase C, the stable fumarase of Escherichia coli, is controlled by the soxRS regulon. Proc. Natl. Acad. Sci. USA, 1992, 89, 5892-5896.
51. Bourgeron, T.; Chretien, D.; Poggi-Bach, J.; Doonan, S.; Rabier, D.; Letouze, P.; Munnich, A.; Rotig, A.; Landrieu, P.; Rustin, P. Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. J. Clin. Invest., 1994, 93, 2514-2518.
52. Weaver, T.; Lees, M.; Banaszak, L. Mutations of fumarase that distinguish between the active site and a nearby dicarboxylic acid binding site. Protein Sci., 1997, 6, 834-42.
53. Tomlinson, I. P.; Alam, N. A.; Rowan, A. J.; Barclay, E.; Jaeger, E. E.; Kelsell, D.; Leigh, I.; Gorman, P.; Lamlum, H.; Rahman, S.; Roylance, R. R.; Olpin, S.; Bevan, S.; Barker, K.; Hearle, N.; Houlston, R. S.; Kiuru, M.; Lehtonen, R.; Karhu, A.; Vilkki, S.; Laiho, P.; Eklund, C.; Vierimaa, O.; Aittomaki, K.; Hietala, M.; Sistonen, P.; Paetau, A.; Salovaara, R.; Herva, R.; Launonen, V.; Aaltonen, L. A. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet., 2002, 30, 406-410.
54. Lehtonen, R.; Kiuru, M.; Vanharanta, S.; Sjoberg, J.; Aaltonen, L. M.; Aittomaki, K.; Arola, J.; Butzow, R.; Eng, C.; Husgafvel-Pursiainen, K.; Isola, J.; Jarvinen, H.; Koivisto, P.; Mecklin, J. P.; Peltomaki, P.; Salovaara, R.; Wasenius, V. M.; Karhu, A.; Launonen, V.; Nupponen, N. N.; Aaltonen, L. A. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am. J. Pathol., 2004, 164, 17-22.
55. Campuzano, V.; Montermini, L.; Molto, M. D.; Pianese, L.; Cossee, M.; Cavalcanti, F.; Monros, E.; Rodius, F.; Duclos, F.; Monticelli, A.; Zara, F.; Canizares, J.; Koutnikova, H.; Bidichandani, S. I.; Gellera, C.; Brice, A.; Trouillas, P.; De Michele, G.; Filla, A.; De Frutos, R.; Palau, F.; Patel, P. I.; Di Donato, S.; Mandel, J. L.; Cocozza, S.; Koenig, M.; Pandolfo, M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271, 1423-1427.
56. Lill, R.; Muhlenhoff, U. Iron-sulfur-protein biogenesis in eukaryotes. Trends Biochem. Sci., 2005, 30, 133-141.
57. Rotig, A.; de Lonlay, P.; Chretien, D.; Foury, F.; Koenig, M.; Sidi, D.; Munnich, A.; Rustin, P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet., 1997, 17, 215-7.
58. Muhlenhoff, U.; Richhardt, N.; Ristow, M.; Kispal, G.; Lill, R. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet., 2002, 11, 2025-2036.
59. Puccio, H.; Simon, D.; Cossee, M.; Criqui-Filipe, P.; Tiziano, F.; Melki, J.; Hindelang, C.; Matyas, R.; Rustin, P.; Koenig, M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet., 2001, 27, 181-186.
60. Shoichet, S. A.; Baumer, A. T.; Stamenkovic, D.; Sauer, H.; Pfeiffer, A. F.; Kahn, C. R.; Muller-Wieland, D.; Richter, C.; Ristow, M. Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro. Hum. Mol. Genet., 2002, 11, 815-21.
61. Schulz, T. J.; Thierbach, R.; Voigt, A.; Drewes, G.; Mietzner, B.; Steinberg, P.; Pfeiffer, A. F.; Ristow, M. Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J. Biol. Chem., 2006, 281, 977-981.
62. Thierbach, R.; Schulz, T. J.; Isken, F.; Voigt, A.; Mietzner, B.; Drewes, G.; von Kleist-Retzow, J. C.; Wiesner, R. J.; Magnuson, M. A.; Puccio, H.; Pfeiffer, A. F.; Steinberg, P.; Ristow, M. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum. Mol. Genet., 2005, 14, 3857-3864.
63. Awad, M. M.; Enslen, H.; Boylan, J. M.; Davis, R. J.; Gruppuso, P. A. Growth regulation via p38 mitogen-activated protein kinase in developing liver. J. Biol. Chem., 2000, 275, 38716-21.
64. Iyoda, K.; Sasaki, Y.; Horimoto, M.; Toyama, T.; Yakushijin, T.; Sakakibara, M.; Takehara, T.; Fujimoto, J.; Hori, M.; Wands, J. R.; Hayashi, N. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer, 2003, 97, 3017-3026.
65. Sutton, A.; Imbert, A.; Igoudjil, A.; Descatoire, V.; Cazanave, S.; Pessayre, D.; Degoul, F. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet. Genomics, 2005, 15, 311-319.
66. Li, H.; Kantoff, P. W.; Giovannucci, E.; Leitzmann, M. F.; Gaziano, J. M.; Stampfer, M. J.; Ma, J. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res., 2005, 65, 2498-2504.
67. Moschos, M. P. Selenoprotein P. Cell. Mol. Life Sci., 2000, 57, 1836-1845.
68. Meplan, C.; Crosley, L. K.; Nicol, F.; Beckett, G. J.; Howie, A. F.; Hill, K. E.; Horgan, G.; Mathers, J. C.; Arthur, J. R.; Hesketh, J. E. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J., 2007, 21, 3063-3074.
69. Cooper, M. L.; Adami, H. O.; Gronberg, H.; Wiklund, F.; Green, F. R.; Rayman, M. P. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res., 2008, 68, 10171-10177.
70. Hirano, M.; DiMauro, S. ANT1, Twinkle, POLG, and TP: new genes open our eyes to ophthalmoplegia. Neurology, 2001, 57, 2163-2165.
71. Bolden, A.; Noy, G. P.; Weissbach, A. DNA polymerase of mitochondria is a gamma-polymerase. J. Biol. Chem., 1977, 252, 3351-3356.
72. Ropp, P. A.; Copeland, W. C. Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. Genomics, 1996, 36, 449-58.
73. Rovio, A. T.; Marchington, D. R.; Donat, S.; Schuppe, H. C.; Abel, J.; Fritsche, E.; Elliott, D. J.; Laippala, P.; Ahola, A. L.; McNay, D.; Harrison, R. F.; Hughes, B.; Barrett, T.; Bailey, D. M.; Mehmet, D.; Jequier, A. M.; Hargreave, T. B.; Kao, S. H.; Cummins, J. M.; Barton, D. E.; Cooke, H. J.; Wei, Y. H.; Wichmann, L.; Poulton, J.; Jacobs, H. T. Mutations at the mitochondrial DNA polymerase (POLG) locus associated with male infertility. Nat. Genet., 2001, 29, 261-262.
74. Blomberg Jensen, M.; Leffers, H.; Petersen, J. H.; Daugaard, G.; Skakkebaek, N. E.; Rajpert-De Meyts, E. Association of the polymorphism of the CAG repeat in the mitochondrial DNA polymerase gamma gene (POLG) with testicular germ-cell cancer. Ann. Oncol., 2008, 19, 1910-1914.
75. Petros, J. A.; Baumann, A. K.; Ruiz-Pesini, E.; Amin, M. B.; Sun, C. Q.; Hall, J.; Lim, S.; Issa, M. M.; Flanders, W. D.; Hosseini, S. H.; Marshall, F. F.; Wallace, D. C. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. USA, 2005, 102, 719-724.
76. King, M. P.; Attardi, G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science, 1989, 246, 500-503.
77. Evans, A. R.; Limp-Foster, M.; Kelley, M. R. Going APE over ref-1. Mutat. Res., 2000, 461, 83-108.
78. Polyak, K.; Li, Y.; Zhu, H.; Lengauer, C.; Willson, J. K.; Markowitz, S. D.; Trush, M. A.; Kinzler, K. W.; Vogelstein, B. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet., 1998, 20, 291-293.
79. Habano, W.; Nakamura, S.; Sugai, T. Microsatellite instability in the mitochondrial DNA of colorectal carcinomas: evidence for mismatch repair systems in mitochondrial genome. Oncogene, 1998, 17, 1931-1937.
80. Sanchez-Cespedes, M.; Parrella, P.; Nomoto, S.; Cohen, D.; Xiao, Y.; Esteller, M.; Jeronimo, C.; Jordan, R. C.; Nicol, T.; Koch, W. M.; Schoenberg, M.; Mazzarelli, P.; Fazio, V. M.; Sidransky, D. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res. 2001, 61, 7015-7019.
81. Habano, W.; Sugai, T.; Yoshida, T.; Nakamura, S. Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. Int. J. Cancer, 1999, 83, 625-629.
82. Parrella, P.; Xiao, Y.; Fliss, M.; Sanchez-Cespedes, M.; Mazzarelli, P.; Rinaldi, M.; Nicol, T.; Gabrielson, E.; Cuomo, C.; Cohen, D.; Pandit, S.; Spencer, M.; Rabitti, C.; Fazio, V. M.; Sidransky, D. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res., 2001, 61, 7623-7626.
83. Zhou, S.; Kachhap, S.; Sun, W.; Wu, G.; Chuang, A.; Poeta, L.; Grumbine, L.; Mithani, S. K.; Chatterjee, A.; Koch, W.; Westra, W. H.; Maitra, A.; Glazer, C.; Carducci, M.; Sidransky, D.; McFate, T.; Verma, A.; Califano, J. A. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc. Natl. Acad. Sci. USA, 2007, 104, 7540-7545.
84. Fliss, M. S.; Usadel, H.; Caballero, O. L.; Wu, L.; Buta, M. R.; Eleff, S. M.; Jen, J.; Sidransky, D. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science, 2000, 287, 2017-2019.
85. Kirches, E.; Michael, M.; Woy, C.; Schneider, T.; Warich-Kirches, M.; Schneider-Stock, R.; Winkler, K.; Wittig, H.; Dietzmann, K. Loss of heteroplasmy in the displacement loop of brain mitochondrial DNA in astrocytic tumors. Genes Chromosomes Cancer, 1999, 26, 80-83.
86. Kirches, E.; Krause, G.; Warich-Kirches, M.; Weis, S.; Schneider, T.; Meyer-Puttlitz, B.; Mawrin, C.; Dietzmann, K. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples. Int. J. Cancer, 2001, 93, 534-538.
87. Montanini, L.; Regna-Gladin, C.; Eoli, M.; Albarosa, R.; Carrara, F.; Zeviani, M.; Bruzzone, M. G.; Broggi, G.; Boiardi, A.; Finocchiaro, G. Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. J. Neurooncol., 2005, 74, 87-89.
88. Kirches, E.; Mawrin, C.; Schneider-Stock, R.; Krause, G.; Scherlach, C.; Dietzmann, K. Mitochondrial DNA as a clonal tumor cell marker: gliomatosis cerebri. J. Neurooncol., 2003, 61, 1-5.
89. Wong, L. J.; Lueth, M.; Li, X. N.; Lau, C. C.; Vogel, H. Detection of mitochondrial DNA mutations in the tumor and cerebrospinal fluid of medulloblastoma patients. Cancer Res., 2003, 63, 3866-3871.
90. Jenuth, J. P.; Peterson, A. C.; Shoubridge, E. A. Tissue-specific selection for different mtDNA genotypes in heteroplasmic mice. Nat. Genet., 1997, 16, 93-95.
91. Habano, W.; Sugai, T.; Nakamura, S. I.; Uesugi, N.; Yoshida, T.; Sasou, S. Microsatellite instability and mutation of mitochondrial and nuclear DNA in gastric carcinoma. Gastroenterology, 2000, 118, 835-841.
92. Coller, H. A.; Khrapko, K.; Bodyak, N. D.; Nekhaeva, E.; Herrero-Jimenez, P.; Thilly, W. G. High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nat. Genet., 2001, 28, 147-150.
93. Matsuyama, W.; Nakagawa, M.; Wakimoto, J.; Hirotsu, Y.; Kawabata, M.; Osame, M. Mitochondrial DNA mutation correlates with stage progression and prognosis in non-small cell lung cancer. Hum. Mutat., 2003, 21, 441-443.
94. Mountain, C. F. Revisions in the International System for Staging Lung Cancer. Chest, 1997, 111, 1710-1717.
95. Lievre, A.; Chapusot, C.; Bouvier, A. M.; Zinzindohoue, F.; Piard, F.; Roignot, P.; Arnould, L.; Beaune, P.; Faivre, J.; Laurent-Puig, P. Clinical value of mitochondrial mutations in colorectal cancer. J. Clin. Oncol., 2005, 23, 3517-3525.
96. Ha, P. K.; Tong, B. C.; Westra, W. H.; Sanchez-Cespedes, M.; Parrella, P.; Zahurak, M.; Sidransky, D.; Califano, J. A. Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin. Cancer Res., 2002, 8, 2260-2265.
97. Isaacs, C.; Cavalli, L. R.; Cohen, Y.; Pennanen, M.; Shankar, L. K.; Freedman, M.; Singh, B.; Liu, M.; Gallagher, A.; Rone, J. D.; Dickson, R. B.; Sidransky, D.; Haddad, B. R. Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients. Breast Cancer Res. Treat., 2004, 84, 99-105.
98. Maitra, A.; Cohen, Y.; Gillespie, S. E.; Mambo, E.; Fukushima, N.; Hoque, M. O.; Shah, N.; Goggins, M.; Califano, J.; Sidransky, D.; Chakravarti, A. The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res., 2004, 14, 812-819.
99. Zhou, S.; Kassauei, K.; Cutler, D. J.; Kennedy, G. C.; Sidransky, D.; Maitra, A.; Califano, J. An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. J. Mol. Diagn., 2006, 8, 476-482.
100. Sui, G.; Zhou, S.; Wang, J.; Canto, M.; Lee, E. E.; Eshleman, J. R.; Montgomery, E. A.; Sidransky, D.; Califano, J. A.; Maitra, A. Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Mol. Cancer, 2006, 5, 73.
101. Jakupciak, J. P.; Maragh, S.; Markowitz, M. E.; Greenberg, A. K.; Hoque, M. O.; Maitra, A.; Barker, P. E.; Wagner, P. D.; Rom, W. N.; Srivastava, S.; Sidransky, D.; O'Connell, C. D. Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer, 2008, 8, 285.